Phase II study of gefitinib in patients with advanced salivary gland cancers

Head and Neck

Volumn 37, Issue 5, 2015, Pages 644-649

  Jakob, John A ^a,b   Kies, Merrill S ^a   Glisson, Bonnie S ^a   Kupferman, Michael E ^a   Liu, Diane D ^a   Lee, J Jack ^a   El Naggar, Adel K ^a   Gonzalez Angulo, Ana M ^a   Blumenschein, George R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

adenoid cystic carcinoma; gefitinib; non adenoid cystic carcinoma; response to therapy; salivary gland cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ABDOMINAL CRAMP; ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FOLLICULITIS; HUMAN; MALE; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYOEPITHELIOMA; NAIL DISEASE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SALIVARY GLAND ADENOCARCINOMA; SALIVARY GLAND CANCER; SALIVARY GLAND CARCINOMA; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CARCINOMA, ADENOID CYSTIC; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REMISSION; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOID CYSTIC; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; QUINAZOLINES; REMISSION INDUCTION; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84928138868     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23647     Document Type: Article

References (22)

1. Adelstein DJ, Rodriguez CP,. What is new in the management of salivary gland cancers? Curr Opin Oncol 2011; 23: 249-253.
2. Speight PM, Barrett AW,. Salivary gland tumours. Oral Dis 2002; 8: 229-240.
3. NCCN. Head and Neck Cancers: Salivary Gland Cancers. In: National Comprehensive Cancer Network version 2. 2012 edition. Available at: http://www.nccn.org. Accessed November 6, 2012.
4. Vered M, Braunstein E, Buchner A,. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002; 24: 632-636.
5. Choi S, Sano D, Cheung M, et al. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2008; 14: 5081-5089.
6. Gibbons MD, Manne U, Carroll WR, Peters GE, Weiss HL, Grizzle WE,. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands. Laryngoscope 2001; 111: 1373-1378.
7. Williams MD, Roberts DB, Kies MS, Mao L, Weber RS, El-Naggar AK,. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 2010; 16: 2266-2274.
8. Ito FA, Ito K, Coletta RD, Graner E, de Almeida OP, Lopes MA,. Salivary gland tumors: immunohistochemical study of EGF, EGFR, ErbB-2, FAS and Ki-67. Anal Quant Cytol Histol 2009; 31: 280-287.
9. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
10. Kramar A, Potvin D, Hill C,. Multistage designs for phase II clinical trials: statistical issues in cancer research. Br J Cancer 1996; 74: 1317-1320.
11. Locati LD, Bossi P, Perrone F, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009; 45: 574-578.
12. Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25: 3978-3984.
13. Haddad R, Colevas AD, Krane JF, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003; 39: 724-727.
14. Glisson B, Colevas AD, Haddad R, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 2004; 10: 944-946.
15. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23: 585-590.
16. Pfeffer MA, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M,. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007; 43: 33-36.
17. Ghosal N, Mais K, Shenjere P, et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Maxillofac Surg 2011; 49: 510-515.
18. Zhang J, Peng B, Chen X,. Expressions on nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11: 7334-7343.
19. Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 2012; 23: 1562-1570.
20. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
21. Vidal L, Tsao MS, Pond GR, et al. Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 2009; 31: 1006-1012.
22. Dahse R, Kosmehl H,. Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. Br J Cancer 2008; 99: 90-92.